Evidence map›Paper›PMID 39763734›Full record

ArticlebioRxiv : the preprint server for biology2024

A new class of penicillin-binding protein inhibitors to address drug-resistant

Tsuyoshi Uehara, Allison L Zulli, Brittany Miller, Lindsay M Avery, Steven A Boyd, Cassandra L Chatwin, Guo-Hua Chu, Anthony S Drager, Mitchell Edwards, Susan G Emeigh Hart and 20 more

Abstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

30 authors.

Tsuyoshi UeharaVenatorx Pharmaceuticals, Inc., Malvern, PA, USA.ORCID 0000-0001-6994-4286
Allison L ZulliVenatorx Pharmaceuticals, Inc., Malvern, PA, USA.
Brittany MillerVenatorx Pharmaceuticals, Inc., Malvern, PA, USA.
Lindsay M AveryVenatorx Pharmaceuticals, Inc., Malvern, PA, USA.
Steven A BoydVenatorx Pharmaceuticals, Inc., Malvern, PA, USA.ORCID 0000-0002-8460-2310
Cassandra L ChatwinVenatorx Pharmaceuticals, Inc., Malvern, PA, USA.
Guo-Hua ChuVenatorx Pharmaceuticals, Inc., Malvern, PA, USA.
Anthony S DragerVenatorx Pharmaceuticals, Inc., Malvern, PA, USA.
Mitchell EdwardsVenatorx Pharmaceuticals, Inc., Malvern, PA, USA.
Susan G Emeigh HartVenatorx Pharmaceuticals, Inc., Malvern, PA, USA.
Cullen L MyersVenatorx Pharmaceuticals, Inc., Malvern, PA, USA.ORCID 0000-0002-5789-2260
Gopinath RongalaVenatorx Pharmaceuticals, Inc., Malvern, PA, USA.
Annie StevensonVenatorx Pharmaceuticals, Inc., Malvern, PA, USA.
Kyoko UeharaVenatorx Pharmaceuticals, Inc., Malvern, PA, USA.
Fan YiVenatorx Pharmaceuticals, Inc., Malvern, PA, USA.
Bibo WangBioDuro-Sundia, Beijing, China.
Zhenwu LiuBioDuro-Sundia, Beijing, China.
Mingyue WangBioDuro-Sundia, Beijing, China.
Zhichao ZhaoBioDuro-Sundia, Beijing, China.
Xinming ZhouBioDuro-Sundia, Beijing, China.
Haiyan ZhaoBioDuro-Sundia, Beijing, China.
Caleb M StrattonDepartment of Biochemistry & Molecular Biology, University of South Alabama, Mobile, AL, USA.
Sandeepchowdary BalaDepartment of Biochemistry & Molecular Biology, University of South Alabama, Mobile, AL, USA.ORCID 0000-0001-6673-0055
Christopher DaviesDepartment of Biochemistry & Molecular Biology, University of South Alabama, Mobile, AL, USA.ORCID 0000-0002-6687-4064
Rok TkavcHenry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, MD, USA.ORCID 0000-0002-1445-8085
Ann E JerseDepartment of Microbiology and Immunology, Uniformed Services University of the Health Sciences, Bethesda, MD, USA.
Daniel C PevearVenatorx Pharmaceuticals, Inc., Malvern, PA, USA.
Christopher J BurnsVenatorx Pharmaceuticals, Inc., Malvern, PA, USA.
Denis M DaigleVenatorx Pharmaceuticals, Inc., Malvern, PA, USA.ORCID 0000-0001-9287-2997
Stephen M CondonVenatorx Pharmaceuticals, Inc., Malvern, PA, USA.

Funding

New class of PBP inhibitors to address PBP2-mediated resistance in Neisseria gonorrhoeaeR01AI141239 · NIAID · VENATORX PHARMACEUTICALS, INC. · PI DAIGLE, DENIS MARC · 2019 to 2023
$7.5M
NIAID NIH HHS R01 AI141239
6 · The paper itself

Abstract

β-Lactams are the most widely used antibiotics for the treatment of bacterial infections because of their proven track record of safety and efficacy. However, susceptibility to β-lactam antibiotics is continually eroded by resistance mechanisms. Emerging multidrug-resistant (MDR)

Indexed as

antibioticborongonorrheanon-β-lactamPBP inhibitorpenicillin-binding protein

Identifiers

PMID39763734
PMCPMC11703265

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.